Key facts
- This page summarizes Kumar Budur's Form 4 filing for Harmony Biosciences Holdings, Inc. (HRMY).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 03 May 2024, 08:05.
Kumar Budur - 01 May 2024 Form 4 Insider Report for Harmony Biosciences Holdings, Inc. (HRMY)
- Reporting relationship
- CHIEF MEDICAL OFFICER
- Issuer ticker
- HRMY
- Reported as of
- 01 May 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 May 2024, 08:05:07 UTC
- Prior SEC filing
- 26 Jan 2024
- Next SEC filing
- 28 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christian Ulrich, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Kumar Budur filed Form 4 for Harmony Biosciences Holdings, Inc. (HRMY) on 03 May 2024.
Change
- Previous filing in this sequence was filed on 26 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
HRMY
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +75,000
- Change %
- Price
- $0.000000
- Shares after
- 75,000
- Date
- 01 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 75,000
- Exercise price
- $30.27
- Footnotes
- F1
HRMY
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +75,000
- Change %
- Price
- $0.000000
- Shares after
- 75,000
- Date
- 01 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 75,000
- Exercise price
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The stock option vests with respect to 25% of the underlying shares on May 1, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
Footnote F2
The restricted stock units shall vest in four equal annual installments beginning on May 1, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.